CD4 and neoplasm: ACM derived from OGJ patients with late-stage tumours significantly increased the expression of CD62L on the surface of CD4+ T cells compared with untreated cells (untrx: 26.73 ± 11.18 vs. late-stage: 37.97 ± 12.9%, p = 0.01) (Fig. 1A).